Skip to content
type1.science
Phase 3RecruitingNCT06630585

Tirzepatide as an adjunct to automated insulin delivery

Swiss randomized phase 3 study testing tirzepatide as an add-on to usual care in adults with type 1 diabetes using automated insulin delivery.

Primary endpoints

  • Change in time-in-range at week 16

Results so far

No results posted. The registry still lists the study as recruiting even though its estimated June 2026 primary and study-completion dates have passed; the record was last updated on 26 January 2026, so its timeline may be stale.